At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 26 target
Drug / intervention
BL-M07D1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Initial Efficacy of BL-M07D1 for Injection in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
In Brief
A Phase 1 clinical trial evaluating BL-M07D1 for Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors. Currently recruiting, targeting 26 participants across 1 site.
Detailed Summary
Evaluation of BL-M07D1 for injection in Phase I clinical study of safety, tolerability, pharmacokinetic Characteristics, and initial efficacy in patients with locally advanced or metastatic digestive tract tumors and other solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsSystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 1Recruiting
202320242025202620272028
First PostedNov 2022
Enrollment StartJan 2023
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedNov 30, 2022
Enrollment StartJan 5, 2023
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 3.9 yearsPosted 3.6 years agoPrimary completion in 5 months
Interventions
BL-M07D1drug
Administration by intravenous infusion